Alnylam Pharmaceuticals, Inc.
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
Last updated:
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
Status:
Application
Type:
Utility
Filling date:
7 Jul 2020
Issue date:
27 May 2021